<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ferric carboxymaltose: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ferric carboxymaltose: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ferric carboxymaltose: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="90344" href="/d/html/90344.html" rel="external">see "Ferric carboxymaltose: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="134691" href="/d/html/134691.html" rel="external">see "Ferric carboxymaltose: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F21196340"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Injectafer</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F21099107"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Iron Preparations</li></ul></div>
<div class="block doa drugH1Div" id="F21283745"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: Route of administration: </b>IV iron replacement is preferred over oral replacement in several clinical situations (eg, poor GI absorption, lack of response to or poor tolerability of oral iron, need for rapid repletion, chronic kidney disease, active inflammatory bowel disease, cancer, chronic or extensive blood loss) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Auerbach.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Auerbach.1'])">Ref</a></span>). <b>Dosage expression: </b>Dose is expressed in mg of elemental iron. <b>Test dose: </b>A test dose is not required<b>.</b></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea1faddf-83d5-47dd-8983-0f9025bbcc3c">Chemotherapy-associated anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chemotherapy-associated anemia (off-label use):</b>
<b>IV:</b> 15 mg/kg (maximum dose: 750 mg) once weekly for 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34653287']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34653287'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="035e1654-7eac-49da-83bd-23b3e0ca305a">Iron-deficiency anemia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia</b>
<b>, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">≥50 kg:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Two-dose regimen: </i>
<b>IV:</b> 750 mg once; after ≥7 days, administer a second dose of 750 mg once; maximum dose: 1.5 g per treatment course.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Single-dose regimen: </i>
<b>IV:</b> 15 mg/kg as a single dose; maximum dose: 1 g.</p>
<p style="text-indent:-2em;margin-left:4em;">&lt;50 kg: <b>IV:</b> 15 mg/kg once; after ≥7 days, administer a second dose of 15 mg/kg once.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ba109ea-8235-47ea-8739-d9e3beef6559">Iron-deficiency anemia in inflammatory bowel disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia in inflammatory bowel disease (off-label use):</b>
<b>IV:</b> 500 to 1,000 mg/dose on day 1 (and if needed based on hemoglobin values, days 8 and 15); patients &lt;67 kg received a maximum of 500 mg per infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25518052','lexi-content-ref-21699794']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25518052','lexi-content-ref-21699794'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea0e3bc6-ee65-4767-8dde-cfee8c6ba7c8">Iron deficiency in patients with heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron deficiency in patients with heart failure: Note:</b> Iron deficiency is defined as a serum ferritin level &lt;100 mcg/L or a serum ferritin level of 100 to 300 mcg/L with transferrin saturation &lt;20% with or without anemia. There are no data for dosing if hemoglobin is ≥15 g/dL.</p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Ferric</b>
<b> Carboxymaltose IV Dosing for Iron Deficiency in Patients With Heart Failure<sup>a,b</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left"></th>
<th align="left" colspan="3">
<p style="text-indent:0em;">
<b>Weight &lt;70 kg</b></p></th>
<th align="left" colspan="3">
<p style="text-indent:0em;">
<b>Weight ≥70 kg</b></p></th></tr>
<tr>
<th align="left"></th>
<th align="left">
<p style="text-indent:0em;">Hb &lt;10 g/dL</p></th>
<th align="left">
<p style="text-indent:0em;">Hb 10 to 14 g/dL</p></th>
<th align="left">
<p style="text-indent:0em;">Hb &gt;14 to &lt;15 g/dL</p></th>
<th align="left">
<p style="text-indent:0em;">Hb &lt;10 g/dL</p></th>
<th align="left">
<p style="text-indent:0em;">Hb 10 to 14 g/dL</p></th>
<th align="left">
<p style="text-indent:0em;">Hb &gt;14 to &lt;15 g/dL</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="7">
<p style="text-indent:0em;">
<sup>a</sup> There are no available data for dosing beyond 36 weeks or in patients with a hemoglobin of ≥15 g/dL.</p></td></tr>
<tr>
<td align="left" colspan="7">
<p style="text-indent:0em;">
<sup>b</sup> Hb = hemoglobin; ID = iron deficient.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Day 1</b></p></td>
<td align="left">
<p style="text-indent:0em;">1 g</p></td>
<td align="left">
<p style="text-indent:0em;">1 g</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg</p></td>
<td align="left">
<p style="text-indent:0em;">1 g</p></td>
<td align="left">
<p style="text-indent:0em;">1 g</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Week 6</b>
<b></b></p></td>
<td align="left">
<p style="text-indent:0em;">500 mg</p></td>
<td align="left">
<p style="text-indent:0em;">No dose</p></td>
<td align="left">
<p style="text-indent:0em;">No dose</p></td>
<td align="left">
<p style="text-indent:0em;">1 g</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg</p></td>
<td align="left">
<p style="text-indent:0em;">No dose</p></td></tr>
<tr>
<td align="left"></td>
<td align="left" colspan="6">
<p style="text-indent:0em;">
<b>Recheck iron studies, if iron deficiency persists at weeks 12, 24, or 36 then redose as needed.</b></p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Week 12</b></p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Week 24</b></p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Week 36</b></p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td>
<td align="left">
<p style="text-indent:0em;">500 mg, only if ID</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> The Ganzoni equation has been recommended as an alternative method to calculate total iron deficit and guide dosing. Replete the iron deficit with 500 mg to 1 g dose(s) every ≥7 days as needed (eg, if iron deficit is 1.5 g, administer 750 mg once and 750 mg again in ≥7 days for a total of 1.5 g). Recheck iron studies every 3 to 6 months and replete again if iron deficiency persists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37137386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37137386'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Iron deficit (mg) = weight (kg)<sup>a</sup> × (target hemoglobin of 15 g/dL − actual hemoglobin in g/dL) × 2.4 + 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;">
<sup>a</sup> Actual body weight; for patients with obesity, use ideal body weight.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e759f864-e1bb-47cb-a1f8-51df2a555051">Perioperative iron deficiency anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Perioperative iron deficiency anemia (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Optimal dose has not been established; example regimen is provided below (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27996086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27996086'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 15 to 20 mg/kg (maximum dose: 1 <b>g</b>) once on postoperative day 1 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36375780','lexi-content-ref-27570088','lexi-content-ref-31036337']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36375780','lexi-content-ref-27570088','lexi-content-ref-31036337'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f697f01-66fe-41f3-8c4d-7ff9a727a5e7">Restless legs syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Restless legs syndrome (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use as an alternative to oral iron repletion for patients with malabsorption, intolerance or lack of response to oral therapy, or need for rapid response to therapy; not recommended for initiation of therapy in patients with serum ferritin &gt;100 mcg/L or transferrin saturation (TSAT) ≥45% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29425576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29425576'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>1 g as a single dose. May repeat at least 12 weeks after initial infusion based on initial response, recurrence of restless legs syndrome symptoms, and if serum ferritin &lt;300 mcg/L and TSAT &lt;45% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29425576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29425576'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990490"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Chronic kidney disease, nondialysis dependent: No dosage adjustment necessary (indicated for use in nondialysis CKD)</p></div>
<div class="block doha drugH1Div" id="F50987775"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F21283746"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F56460004"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="134691" href="/d/html/134691.html" rel="external">see "Ferric carboxymaltose: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Dose is expressed in milligrams of elemental iron.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="035e1654-7eac-49da-83bd-23b3e0ca305a">Iron-deficiency anemia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Two-dose regimen: </i>IV: 15 mg/kg/dose for 2 doses separated by ≥7 days; maximum dose: 750 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Single-</i>
<i>dose regimen</i>: Limited data available: IV: 15 to 20 mg/kg/dose as a single dose; maximum dose: 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30881896','lexi-content-ref-27776750','lexi-content-ref-33230080','lexi-content-ref-28844092']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30881896','lexi-content-ref-27776750','lexi-content-ref-33230080','lexi-content-ref-28844092'])">Ref</a></span>). Dosing based on calculated iron deficit using the Ganzoni equation has also been reported; reported doses range from 10 to 32 mg/kg/dose with maximum single doses of 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25326048','lexi-content-ref-32729200','lexi-content-ref-29266387','lexi-content-ref-28844092','lexi-content-ref-UKManu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25326048','lexi-content-ref-32729200','lexi-content-ref-29266387','lexi-content-ref-28844092','lexi-content-ref-UKManu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6cf4232d-279f-4d01-8509-c3b0998298e1">Restless sleep disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Restless sleep disorder:</b> Very limited data available: Children ≥5 years and Adolescents: IV: 15 mg/kg as a single dose; maximum dose: 750 mg/dose. Dosing based on a single study comparing IV ferric carboxymaltose with oral ferrous sulfate (n=30; 15 patients received ferric carboxymaltose); the ferric carboxymaltose group experienced more improvement and fewer adverse effects than the oral ferrous sulfate group (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32840615']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32840615'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F56460005"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Based on experience in adults, no adjustments are likely needed in nondialysis-dependent patients with chronic kidney disease.</p></div>
<div class="block dohp drugH1Div" id="F56460006"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F21304014"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Endocrine &amp; metabolic: Hypophosphatemia (children, adolescents: 13%; adults: 1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (children, adolescents, adults: ≤4%), hypertension (1% to 4%), hypotension (≤1%), increased systolic blood pressure (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin (≤3%), skin rash (children, adolescents: 8%; adults: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (1%), gastrointestinal infection (children, adolescents: 3%), nausea (1% to 7%), vomiting (children, adolescents, adults: ≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased platelet count (children, adolescents: 3%), decreased white blood cell count (children, adolescents: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (children, adolescents, adults: 1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (children, adolescents, adults: 3% to 8%; including bleeding at injection site, bruising at injection site, discomfort at injection site, erythema at injection site, hematoma at injection site, injection-site numbness [hypoesthesia], injection-site pruritus, irritation at injection site, pain at injection site, rash at injection site, skin discoloration at injection site [≤1%], and swelling at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (1% to 2%), headache (children, adolescents: 5%; adults: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (children, adolescents: 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, constipation, diarrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased gamma-glutamyl transferase</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Sneezing</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort, syncope, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, back pain, osteomalacia (hypophosphatemic)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F21099098"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ferric carboxymaltose or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F21283284"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious hypersensitivity reactions, including anaphylactic-type reactions (some life-threatening and fatal) have been reported. Signs/symptoms of serious hypersensitivity reaction include shock, hypotension, loss of consciousness, and/or collapse. Equipment for resuscitation, medication, and trained personnel experienced in handling emergencies should be immediately available during infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: Transient elevations in systolic blood pressure (sometimes with facial flushing, dizziness, or nausea) were observed in studies; usually occurred immediately after dosing and resolved within 30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypophosphatemia: Symptomatic hypophosphatemia, with serious outcomes (eg, fractures, osteomalacia), has been reported. Most cases occurred after repeated exposure in patients without a history of renal impairment and resolved within 3 months; however, may occur after 1 dose. Risk factors may include a history of GI disorders associated with malabsorption of fat-soluble vitamins or phosphate, inflammatory bowel disease, use (current or prior) of medications that affect proximal renal tubular function, hyperparathyroidism, vitamin D deficiency, and malnutrition. Correct hypophosphatemia prior to prescribing initial or repeat treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Laboratory alterations: Lab assays may overestimate serum iron and transferrin bound irons for ~24 hours after infusion.</p></div>
<div class="block dosfc drugH1Div" id="F21963469"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Each mL of Injectafer contains 50 mg of elemental iron</p></div>
<div class="block foc drugH1Div" id="F21196341"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Injectafer: 100 mg/2 mL (2 mL); 750 mg/15 mL (15 mL)</p></div>
<div class="block geq drugH1Div" id="F21196339"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F22686900"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Injectafer Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/2 mL (per mL): $115.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg/15 mL (per mL): $115.67</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F21283749"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer as slow IV push (undiluted) at a rate of ~100 mg/minute (doses ≤750 mg) or over 15 minutes (1 g dose). May also administer as an IV infusion (diluted) over at least 15 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Avoid extravasation (may cause persistent discoloration at the extravasation site). Monitor; if extravasation occurs, discontinue administration at that site.</p></div>
<div class="block admp drugH1Div" id="F56460009"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV: In prospective and retrospective pediatric studies, doses were infused over 15 to 30 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30881896','lexi-content-ref-27776750','lexi-content-ref-33230080']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30881896','lexi-content-ref-27776750','lexi-content-ref-33230080'])">Ref</a></span>). Administer diluted solution over ≥15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>); maximum infusion time of 60 minutes has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25326048']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25326048'])">Ref</a></span>). For doses of 750 mg, may administer undiluted as a slow IV push at a rate of ~100 mg/minute; for doses of 1,000 mg, administer over 15 minutes. Avoid extravasation (may cause persistent discoloration at the extravasation site). If extravasation occurs, discontinue administration at that site.</p></div>
<div class="block use drugH1Div" id="F21099097"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia:</b> Treatment of iron-deficiency anemia (IDA) in adults and pediatric patients ≥1 year of age with intolerance to oral iron or unsatisfactory response to oral iron; treatment of IDA in adults with nondialysis-dependent chronic kidney disease (ND-CKD).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron deficiency in patients with heart failure:</b> Treatment of iron deficiency with or without anemia in adults with New York Heart Association class II or III heart failure to improve exercise capacity.</p></div>
<div class="block off-label drugH1Div" id="F50946856"><span class="drugH1">Use: Off-Label: Adult</span><p>Chemotherapy-associated anemia; Iron-deficiency anemia in inflammatory bowel disease; Perioperative iron deficiency anemia; Restless legs syndrome</p></div>
<div class="block mst drugH1Div" id="F21283278"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ferric carboxymaltose may be confused with ferric gluconate, ferumoxytol</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F21213087"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F21213085"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Dimercaprol: May enhance the nephrotoxic effect of Iron Preparations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Iron Preparations may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F21283281"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Ferric carboxymaltose was not found to cross the placenta in an in vitro placental perfusion study (Malek 2010). Iron transfer to the fetus is regulated by the placenta (BSH [Pavord 2020]; NAS 2020).</p>
<p style="text-indent:0em;margin-top:2em;">There is a risk of adverse maternal reactions (eg, anaphylaxis, hypotension, shock) following use of parenteral iron which may result in fetal bradycardia, especially during the second and third trimesters. Although the risk is rare, immediate treatment for anaphylactoid and/or hypersensitivity reactions should be available (BSH [Pavord 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal iron requirements increase during pregnancy. Untreated iron deficiency and iron-deficiency anemia (IDA) in pregnant patients are associated with adverse pregnancy outcomes, including low birth weight, preterm birth, and increased perinatal mortality (ACOG 2021; BSH [Pavord 2020]). Maternal iron deficiency is also associated with fatigue, increased risk of postpartum depression, and possibly postpartum hemorrhage (BSH [Pavord 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Oral and parenteral iron are effective at replacing iron stores in pregnant patients (ACOG 2021). Most studies note iron therapy improves maternal hematologic parameters; however, data related to clinical outcomes in the mother and neonate are limited (FIGO 2019; NAS 2020; USPSTF [Siu 2015]). Parenteral iron therapy may be used in pregnant patients who cannot tolerate or respond to oral iron, when iron deficiency occurs later in pregnancy, or when malabsorption is present (ACOG 2021; BSH [Pavord 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Ferric carboxymaltose has been evaluated for the treatment of IDA during pregnancy (Breymann 2017; Froessler 2018; Khalafallah 2018; Oskovi-Kaplan 2021; Qassim 2018; Rogozińska 2021; Shim 2018; Shin 2021; Wani 2019). Based on available data, adverse developmental outcomes have not been reported following maternal use of ferric carboxymaltose in pregnancy. However, due to limited safety data in early pregnancy, use of intravenous iron is generally not started until the second or third trimester (ACOG 2021; BSH [Pavord 2020]; FIGO 2019).</p>
<p style="text-indent:0em;margin-top:2em;">IV iron may be considered for the treatment of restless legs syndrome in pregnant patients with serum ferritin &lt;30 ng/mL who have failed oral iron; use of IV iron should be avoided during the first trimester (Picchietti 2015; Schneider 2015).</p></div>
<div class="block brc drugH1Div" id="F21283283"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Iron is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Endogenous iron concentrations in breast milk vary by postpartum age and are lower than concentrations in the maternal plasma (Dorea 2000; Emmett 1997). Breast milk concentrations of iron are maintained in lactating patients with mild to moderate iron-deficiency anemia (IDA), but concentrations decrease if IDA is moderate to severe (El-Farrash 2012) or severe (Kumar 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">Iron concentrations in breast milk increase following maternal administration of ferric carboxymaltose; highest concentrations were observed 24 hours following administration to 11 postpartum patients with IDA (Breymann 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">Ferric carboxymaltose has been evaluated in multiple studies for the treatment of postpartum IDA (Sultan 2019; Vanobberghen 2021). Adverse events in breastfed infants were limited and similar to those observed following maternal use of an oral iron preparation (Breymann 2008). In a study of 57 patients with moderate to severe anemia, a single postpartum dose of ferric carboxymaltose was found to treat anemia and replenish iron reserves for up to 6 months (Kaur 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">Iron deficiency and IDA are associated with adverse effects in postpartum patients (eg, altered cognition, depression, fatigue) that may influence interactions with the infant. Iron supplementation in the postpartum patient should be initiated as soon as possible following delivery when gestational anemia is a concern (WHO 2016). Parenteral iron therapy may be used in postpartum patients with uncorrected anemia at delivery who cannot tolerate, do not respond to, or are noncompliant with oral iron therapy, or the severity of anemia requires prompt management (BSH [Pavord 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F21283804"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Hemoglobin and hematocrit, serum ferritin, transferrin saturation, serum phosphate (in patients at risk for hypophosphatemia who require a repeat course of treatment); vital signs (including blood pressure); monitor for signs/symptoms of hypersensitivity (monitor for ≥30 minutes following the end of administration and until clinically stable); monitor infusion site for extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">Chronic kidney disease: Monitor transferrin saturation and ferritin more frequently following a course of IV iron (KDIGO 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Chemotherapy-associated anemia (off-label use): Iron, total iron-binding capacity, transferrin saturation, or ferritin levels at baseline and periodically (Rizzo 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Iron deficient patients should have serum ferritin assessed 2 to 4 weeks after infusion course is completed; if serum ferritin &gt;50 to 100 ng/mL is not achieved, then another iron dose should be administered (DeLoughery 2017).</p></div>
<div class="block rer drugH1Div" id="F21283472"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Hemoglobin, whole blood:</p>
<p style="text-indent:-2em;margin-left:6em;">Female: 12 to16 g/dL (SI: 120 to 160 g/L) (ABIM 2023).</p>
<p style="text-indent:-2em;margin-left:6em;">Male: 13 to 18 g/dL (SI: 130 to 180 g/L) (ABIM 2023; WHO 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron deficiency (ABIM 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Ferritin, serum: <b>Note:</b> Ferritin is an acute phase reactant; levels may be elevated in the presence of inflammation or infection which is independent of iron status (WHO 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">Female: 24 to 307 ng/mL (SI: 53.9 to 689.8 picomole/L).</p>
<p style="text-indent:-2em;margin-left:6em;">Male: 24 to 336 ng/mL (SI: 53.9 to 755 picomole/L).</p>
<p style="text-indent:-2em;margin-left:4em;">Iron, serum: 50 to 150 mcg/dL (SI: 9 to 26.9 micromole/L).</p>
<p style="text-indent:-2em;margin-left:4em;">Total iron binding capacity, serum: 250 to 310 mcg/dL (SI: 44.8 to 55.5 micromole/L).</p>
<p style="text-indent:-2em;margin-left:4em;">Transferrin saturation: 20% to 50%.</p>
<p style="text-indent:-2em;margin-left:4em;">Transferrin, serum: 200 to 400 mg/dL (SI: 24.6 to 49.2 micromole/L).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic kidney disease-associated anemia:</b> To achieve and maintain target hemoglobin for patients with nondialysis-dependent chronic kidney disease, patients with a transferrin saturation (TSAT) ≤30% and a serum ferritin level ≤500 ng/mL (SI: 1,123.5 picomole/L) will often respond to iron supplementation (Gutiérrez 2021; KDIGO 2012).</p></div>
<div class="block pha drugH1Div" id="F21283470"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ferric carboxymaltose is a colloidal iron (III) hydroxide in complex with carboxymaltose, a carbohydrate polymer that releases iron necessary to the function of hemoglobin, myoglobin, and specific enzyme systems; allows transport of oxygen via hemoglobin. Ferric carboxymaltose is a non-dextran formulation that allows for iron uptake (into reticuloendothelial system) without the release of free iron (Szczech 2010).</p></div>
<div class="block phk drugH1Div" id="F21287590"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~3 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: ~9.7 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 7 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Median: 7 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 0.25 to 1.21 hours following administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (negligible).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23669728"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Fematos | Ferinject | Ferintus | Xefer</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Haem</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bdcarboxy | Carbinject | Encicarb | Fcmalt | Ferinject | Hosit fcm | Inronx | Paldela | Raricap fcm</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Boferin | Ferinject</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Injectafer</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ferinject | Inferject</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Feringect | Ferinject</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Ferrinject</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Ferinject</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29471514">
<a name="29471514"></a>Aapro M, Beguin Y, Bokemeyer C, et al; ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. <i>Ann Oncol</i>. 2018;29(suppl 4):Siv96-Siv110. doi:10.1093/annonc/mdx758<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/29471514/pubmed" id="29471514" target="_blank">29471514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28326596">
<a name="28326596"></a>Aksan A, Işık H, Radeke HH, Dignass A, Stein J. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. <i>Aliment Pharmacol Ther</i>. 2017;45(10):1303-1318.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/28326596/pubmed" id="28326596" target="_blank">28326596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21978726">
<a name="21978726"></a>Allen RP, Adler CH, Du W, Butcher A, Bregman DB, Earley CJ. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centered, placebo-controlled preliminary clinical trial. <i>Sleep Med</i>. 2011;12(9):906-913. doi:10.1016/j.sleep.2011.06.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/21978726/pubmed" id="21978726" target="_blank">21978726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29425576">
<a name="29425576"></a>Allen RP, Picchietti DL, Auerbach M, et al; International Restless Legs Syndrome Study Group (IRLSSG). Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. <i>Sleep Med</i>. 2018;41:27-44. doi:10.1016/j.sleep.2017.11.1126<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/29425576/pubmed" id="29425576" target="_blank">29425576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics Committee on Nutrition. Kleinman RE, Greer FR, eds. <i>Pediatric Nutrition Handbook</i>. 8th ed. American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ABIM.1">
<a name="ABIM.1"></a>American Board of Internal Medicine. Laboratory Test Reference Ranges. <i>Lexi-Drugs</i>. UpToDate Lexidrug. Waltham, MA: UpToDate Inc. https://online.lexi.com. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34293770">
<a name="34293770"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 233: Anemia in pregnancy. <i>Obstet Gynecol. </i>2021;138(2):e55-e64. doi:10.1097/AOG.0000000000004477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/34293770/pubmed" id="34293770" target="_blank">34293770</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Auerbach.1">
<a name="Auerbach.1"></a>Auerbach M. Treatment of iron deficiency anemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37137386">
<a name="37137386"></a>Beavers CJ, Ambrosy AP, Butler J, et al. Iron deficiency in heart failure: a scientific statement from the Heart Failure Society of America. <i>J Card Fail</i>. Published online May 1, 2023. doi:10.1016/j.cardfail.2023.03.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/37137386/pubmed" id="37137386" target="_blank">37137386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18234203">
<a name="18234203"></a>Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. <i>Int J Gynaecol Obstet</i>. 2008;101(1):67-73. doi:10.1016/j.ijgo.2007.10.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/18234203/pubmed" id="18234203" target="_blank">18234203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27278921">
<a name="27278921"></a>Breymann C, Milman N, Mezzacasa A, et al; FER-ASAP investigators. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). <i>J Perinat Med</i>. 2017;45(4):443-453. doi:10.1515/jpm-2016-0050</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30881896">
<a name="30881896"></a>Carman N, Muir R, Lewindon P. Ferric carboxymaltose in the treatment of iron deficiency in pediatric inflammatory bowel disease. <i>Transl Pediatr</i>. 2019;8(1):28-34. doi:10.21037/tp.2019.01.01<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/30881896/pubmed" id="30881896" target="_blank">30881896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27823710">
<a name="27823710"></a>Cho YW, Allen RP, Earley CJ. Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. <i>Sleep Med</i>. 2016;25:16-23. doi:10.1016/j.sleep.2016.06.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/27823710/pubmed" id="27823710" target="_blank">27823710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28189173">
<a name="28189173"></a>DeLoughery TG. Iron deficiency anemia. <i>Med Clin North Am</i>. 2017;101(2):319-332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/28189173/pubmed" id="28189173" target="_blank">28189173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32840615">
<a name="32840615"></a>DelRosso LM, Picchietti DL, Ferri R. Comparison between oral ferrous sulfate and intravenous ferric carboxymaltose in children with restless sleep disorder. <i>Sleep</i>. 2021;44(2):zsaa155. doi:10.1093/sleep/zsaa155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/32840615/pubmed" id="32840615" target="_blank">32840615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25518052">
<a name="25518052"></a>Dignass AU, Gasche C, Bettenworth D, et al; European Crohn’s and Colitis Organisation [ECCO]. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. <i>J Crohns Colitis</i>. 2015;9(3):211-222. doi:10.1093/ecco-jcc/jju009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/25518052/pubmed" id="25518052" target="_blank">25518052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10705077">
<a name="10705077"></a>Dorea JG. Iron and copper in human milk. <i>Nutrition</i>. 2000;16(3):209-220. doi:10.1016/s0899-9007(99)00287-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/10705077/pubmed" id="10705077" target="_blank">10705077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21548016">
<a name="21548016"></a>El-Farrash RA, Ismail EA, Nada AS. Cord blood iron profile and breast milk micronutrients in maternal iron deficiency anemia. <i>Pediatr Blood Cancer</i>. 2012;58(2):233-238. doi:10.1002/pbc.23184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/21548016/pubmed" id="21548016" target="_blank">21548016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9363415">
<a name="9363415"></a>Emmett PM, Rogers IS. Properties of human milk and their relationship with maternal nutrition. <i>Early Hum Dev</i>. 1997;49(suppl):S7-S28. doi:10.1016/s0378-3782(97)00051-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/9363415/pubmed" id="9363415" target="_blank">9363415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21699794">
<a name="21699794"></a>Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. <i>Gastroenterology</i>. 2011;141(3):846-853.e1-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/21699794/pubmed" id="21699794" target="_blank">21699794</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Ferinject (ferric carboxymaltose) [product information]. Melbourne, Australia: Vifor Pharma Pty Ltd; September 2021.</div>
</li>
<li>
<div class="reference">
                  Ferinject (ferric carboxymaltose) [summary of product characteristics]. Paris, France: Vifor France; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ferinject.1">
<a name="Ferinject.1"></a>Ferinject (ferric carboxymaltose) [summary of product characteristics]. Surrey, UK: Vifor Pharma UK Limited; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30710364">
<a name="30710364"></a>FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine. Good clinical practice advice: iron deficiency anemia in pregnancy. <i>Int J Gynaecol Obstet</i>. 2019;144(3):322-324. doi:10.1002/ijgo.12740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/30710364/pubmed" id="30710364" target="_blank">30710364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26817624">
<a name="26817624"></a>Froessler B, Palm P, Weber I, Hodyl NA, Singh R, Murphy EM. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. <i>Ann Surg</i>. 2016;264(1):41-46. doi:10.1097/SLA.0000000000001646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/26817624/pubmed" id="26817624" target="_blank">26817624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29740690">
<a name="29740690"></a>Froessler B, Gajic T, Dekker G, Hodyl NA. Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy. <i>Arch Gynecol Obstet</i>. 2018;298(1):75-82. doi:10.1007/s00404-018-4782-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/29740690/pubmed" id="29740690" target="_blank">29740690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27448465">
<a name="27448465"></a>Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. <i>Sleep Med</i>. 2016;21:1-11. doi:10.1016/j.sleep.2016.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/27448465/pubmed" id="27448465" target="_blank">27448465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24114623">
<a name="24114623"></a>Gomollón F, Gisbert JP. Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide. <i>Drugs</i>. 2013;73(16):1761-1770.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/24114623/pubmed" id="24114623" target="_blank">24114623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34514189">
<a name="34514189"></a>Gutiérrez O. Treatment of iron deficiency anemia in CKD and end-stage kidney disease. <i>Kidney Int Rep. </i>2021;6(9):2261-2269. doi:10.1016/j.ekir.2021.05.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/34514189/pubmed" id="34514189" target="_blank">34514189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36375780">
<a name="36375780"></a>Houry M, Tohme J, Sleilaty G, et al. Effects of ferric carboxymaltose on hemoglobin level after cardiac surgery: a randomized controlled trial. <i>Anaesth Crit Care Pain Med</i>. 2023;42(1):101171. doi:10.1016/j.accpm.2022.101171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/36375780/pubmed" id="36375780" target="_blank">36375780</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Injectafer (ferric carboxymaltose) [prescribing information]. Shirley, NY: American Regent Inc; May 2023.</div>
</li>
<li>
<div class="reference">
                  IOM (Institute of Medicine). <i>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</i>. National Academy Press; 2001.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34079413">
<a name="34079413"></a>Jones JJ, Mundy LM, Blackman N, Shwarz M. Ferric carboxymaltose for anemic perioperative populations: a systematic literature review of randomized controlled trials. <i>J Blood Med</i>. 2021;12:337-359. doi:10.2147/JBM.S295041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/34079413/pubmed" id="34079413" target="_blank">34079413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34268465">
<a name="34268465"></a>Kaur R, Kant S, Haldar P, et al. Single dose of intravenous ferric carboxymaltose prevents anemia for 6 months among moderately or severely anemic postpartum women: a case study from India. <i>Curr Dev Nutr</i>. 2021;5(7):nzab078. doi:10.1093/cdn/nzab078<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/34268465/pubmed" id="34268465" target="_blank">34268465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30502851">
<a name="30502851"></a>Khalafallah AA, Hyppa A, Chuang A, et al. A prospective randomised controlled trial of a single intravenous infusion of ferric carboxymaltose vs single intravenous iron polymaltose or daily oral ferrous sulphate in the treatment of iron deficiency anaemia in pregnancy. <i>Semin Hematol</i>. 2018;55(4):223-234. doi:10.1053/j.seminhematol.2018.04.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/30502851/pubmed" id="30502851" target="_blank">30502851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27570088">
<a name="27570088"></a>Khalafallah AA, Yan C, Al-Badri R, et al. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomised controlled trial. <i>Lancet Haematol</i>. 2016;3(9):e415-e425. doi:10.1016/S2352-3026(16)30078-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/27570088/pubmed" id="27570088" target="_blank">27570088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for anemia in chronic kidney disease (2012). https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference">
                  Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease. <i>Kidney Inter</i>. 2013;3(suppl):1-150. http://kdigo.org/clinical_practice_guidelines/pdf/KDIGO-Anemia%20GL.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33735470">
<a name="33735470"></a>Kirk SE, Scheurer ME, Bernhardt MB, Mahoney DH, Powers JM. Phosphorus levels in children treated with intravenous ferric carboxymaltose. <i>Am J Hematol</i>. 2021;96(6):E215-E218. doi:10.1002/ajh.26165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/33735470/pubmed" id="33735470" target="_blank">33735470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18310187">
<a name="18310187"></a>Kumar A, Rai AK, Basu S, et al. Cord blood and breast milk iron status in maternal anemia. <i>Pediatrics</i>. 2008;121(3):e673-e677. doi:10.1542/peds.2007-1986<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/18310187/pubmed" id="18310187" target="_blank">18310187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25326048">
<a name="25326048"></a>Laass MW, Straub S, Chainey S, Virgin G, Cushway T. Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases. <i>BMC Gastroenterol</i>. 2014;14:184. doi:10.1186/1471-230X-14-184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/25326048/pubmed" id="25326048" target="_blank">25326048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20648927">
<a name="20648927"></a>Malek A. In vitro studies of ferric carboxymaltose on placental permeability using the dual perfusion model of human placenta. <i>Arzneimittelforschung</i>. 2010;60(6a):354-361. doi:10.1055/s-0031-1296300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/20648927/pubmed" id="20648927" target="_blank">20648927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34653287">
<a name="34653287"></a>Makharadze T, Boccia R, Krupa A, Blackman N, Henry DH, Gilreath JA. Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: a randomized, placebo-controlled study (IRON-CLAD).<i> Am J Hematol.</i> 2021;96(12):1639-1646. doi:10.1002/ajh.26376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/34653287/pubmed" id="34653287" target="_blank">34653287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26270434">
<a name="26270434"></a>Markova V, Norgaard A, Jørgensen KJ, et al. Treatment for women with postpartum iron deficiency anaemia. <i>Cochrane Database Syst Rev</i>. 2015;(8):CD010861. doi:10.1002/14651858.CD010861.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/26270434/pubmed" id="26270434" target="_blank">26270434</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27996086">
<a name="27996086"></a>Muñoz M, Acheson AG, Auerbach M, et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. <i>Anaesthesia</i>. 2017;72(2):233-247. doi:10.1111/anae.13773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/27996086/pubmed" id="27996086" target="_blank">27996086</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Academies of Sciences, Engineering, and Medicine. <i>Nutrition During Pregnancy and Lactation: Exploring New Evidence: Proceedings of a Workshop</i>. The National Academies Press; 2020. https://doi.org/10.17226/25841
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32990783">
<a name="32990783"></a>Oskovi-Kaplan ZA, Kilickiran H, Buyuk GN, Ozyer S, Keskin HL, Engin-Ustun Y. Comparison of the maternal and neonatal outcomes of pregnant women whose anemia was not corrected before delivery and pregnant women who were treated with intravenous iron in the third trimester. <i>Arch Gynecol Obstet</i>. 2021;303(3):715-719. doi:10.1007/s00404-020-05817-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/32990783/pubmed" id="32990783" target="_blank">32990783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32729200">
<a name="32729200"></a>Ozsahin H, Schaeppi M, Bernimoulin M, Allard M, Guidard C, van den Ouweland F. Intravenous ferric carboxymaltose for iron deficiency anemia or iron deficiency without anemia after poor response to oral iron treatment: Benefits and risks in a cohort of 144 children and adolescents. <i>Pediatr Blood Cancer</i>. 2020;67(10):e28614. doi:10.1002/pbc.28614<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/32729200/pubmed" id="32729200" target="_blank">32729200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29266387">
<a name="29266387"></a>Papadopoulos M, Patel D, Korologou-Linden R, et al. Safety and efficacy of parenteral iron in children with inflammatory bowel disease. <i>Br J Clin Pharmacol</i>. 2018;84(4):694-699. doi:10.1111/bcp.13493<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/29266387/pubmed" id="29266387" target="_blank">29266387</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31578718">
<a name="31578718"></a>Pavord S, Daru J, Prasannan N, Robinson S, Stanworth S, Girling J; BSH Committee. UK guidelines on the management of iron deficiency in pregnancy. <i>Br J Haematol</i>. 2020;188(6):819-830. doi:10.1111/bjh.16221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/31578718/pubmed" id="31578718" target="_blank">31578718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25553600">
<a name="25553600"></a>Picchietti DL, Hensley JG, Bainbridge JL, et al; International Restless Legs Syndrome Study Group (IRLSSG). Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation. <i>Sleep Med Rev</i>. 2015;22:64-77. doi:10.1016/j.smrv.2014.10.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/25553600/pubmed" id="25553600" target="_blank">25553600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27207191">
<a name="27207191"></a>Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). <i>Eur J Heart Fail</i>. 2016;18(8):891-975.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/27207191/pubmed" id="27207191" target="_blank">27207191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27776750">
<a name="27776750"></a>Powers JM, Shamoun M, McCavit TL, Adix L, Buchanan GR. Intravenous ferric carboxymaltose in children with iron deficiency anemia who respond poorly to oral iron. <i>J Pediatr</i>. 2017;180:212-216. doi:10.1016/j.jpeds.2016.09.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/27776750/pubmed" id="27776750" target="_blank">27776750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-UKManu.1">
<a name="UKManu.1"></a>Refer to UK manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34171281">
<a name="34171281"></a>Rogozińska E, Daru J, Nicolaides M, et al. Iron preparations for women of reproductive age with iron deficiency anaemia in pregnancy (FRIDA): a systematic review and network meta-analysis. <i>Lancet Haematol</i>. 2021;8(7):e503-e512. doi:10.1016/S2352-3026(21)00137-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/34171281/pubmed" id="34171281" target="_blank">34171281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28921558">
<a name="28921558"></a>Qassim A, Mol BW, Grivell RM, et al. Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: A systematic review. <i>Aust N Z J Obstet Gynaecol</i>. 2018;58(1):22-39. doi:10.1111/ajo.12695<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/28921558/pubmed" id="28921558" target="_blank">28921558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20929915">
<a name="20929915"></a>Qunibi WY, Martinez C, Smith M, et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. <i>Nephrol Dial Transplant</i>. 2011;26(5):1599-1607.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/20929915/pubmed" id="20929915" target="_blank">20929915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20975064">
<a name="20975064"></a>Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. <i>J Clin Oncol</i>. 2010;28(33):4996-5010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/20975064/pubmed" id="20975064" target="_blank">20975064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33230080">
<a name="33230080"></a>Sasankan N, Duncan H, Curtis L, et al. Ferric carboxymaltose across all ages in paediatric gastroenterology shows efficacy without increased safety concerns. <i>J Pediatr Gastroenterol Nutr</i>. 2021;72(4):506-510. doi:10.1097/MPG.0000000000003003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/33230080/pubmed" id="33230080" target="_blank">33230080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26498233">
<a name="26498233"></a>Schneider J, Krafft A, Manconi M, et al. Open-label study of the efficacy and safety of intravenous ferric carboxymaltose in pregnant women with restless legs syndrome. <i>Sleep Med</i>. 2015;16(11):1342-1347. doi:10.1016/j.sleep.2015.08.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/26498233/pubmed" id="26498233" target="_blank">26498233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30153811">
<a name="30153811"></a>Shim JY, Kim MY, Kim YJ, et al. Efficacy and safety of ferric carboxymaltose versus ferrous sulfate for iron deficiency anemia during pregnancy: subgroup analysis of Korean women. <i>BMC Pregnancy Childbirth</i>. 2018;18(1):349. doi:10.1186/s12884-018-1817-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/30153811/pubmed" id="30153811" target="_blank">30153811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34011020">
<a name="34011020"></a>Shin HW, Go DY, Lee SW, et al. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: a systematic review and meta-analysis. <i>Medicine (Baltimore)</i>. 2021;100(20):e24571. doi:10.1097/MD.0000000000024571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/34011020/pubmed" id="34011020" target="_blank">34011020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344176">
<a name="26344176"></a>Siu AL; US Preventive Services Task Force. Screening for iron deficiency anemia and iron supplementation in pregnant women to improve maternal health and birth outcomes: US Preventive Services Task Force Recommendation Statement. <i>Ann Intern Med</i>. 2015;163(7):529-536. doi:10.7326/M15-1707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/26344176/pubmed" id="26344176" target="_blank">26344176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31036337">
<a name="31036337"></a>Spahn DR, Schoenrath F, Spahn GH, et al. Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial. <i>Lancet</i>. 2019;393(10187):2201-2212. doi:10.1016/S0140-6736(18)32555-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/31036337/pubmed" id="31036337" target="_blank">31036337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23071262">
<a name="23071262"></a>Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. <i>Ann Oncol</i>. 2013;24(2):475-482.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/23071262/pubmed" id="23071262" target="_blank">23071262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30578747">
<a name="30578747"></a>Sultan P, Bampoe S, Shah R, et al. Oral vs intravenous iron therapy for postpartum anemia: a systematic review and meta-analysis. <i>Am J Obstet Gynecol</i>. 2019;221(1):19.e3-29.e3. doi:10.1016/j.ajog.2018.12.016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/30578747/pubmed" id="30578747" target="_blank">30578747</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20466657">
<a name="20466657"></a>Szczech LA, Bregman DB, Harrington RA, et al. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design. <i>Nephrol Dial Transplant.</i> 2010;25(7):2368-2375.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/20466657/pubmed" id="20466657" target="_blank">20466657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28844092">
<a name="28844092"></a>Tan MLN, Windscheif PM, Thornton G, Gaynor E, Rodrigues A, Howarth L. Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre. <i>Eur J Pediatr</i>. 2017;176(10):1419-1423. doi:10.1007/s00431-017-2995-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/28844092/pubmed" id="28844092" target="_blank">28844092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28643901">
<a name="28643901"></a>Trenkwalder C, Winkelmann J, Oertel W, et al. Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial. <i>Mov Disord</i>. 2017;32(10):1478-1482. doi:10.1002/mds.27040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/28643901/pubmed" id="28643901" target="_blank">28643901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33245866">
<a name="33245866"></a>Vanobberghen F, Lweno O, Kuemmerle A, et al. Efficacy and safety of intravenous ferric carboxymaltose compared with oral iron for the treatment of iron deficiency anaemia in women after childbirth in Tanzania: a parallel-group, open-label, randomised controlled phase 3 trial. <i>Lancet Glob Health</i>. 2021;9(2):e189-e198. doi:10.1016/S2214-109X(20)30448-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/33245866/pubmed" id="33245866" target="_blank">33245866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31781389">
<a name="31781389"></a>Wani S, Noushad M, Ashiq S. REGAIN STUDY: retrospective study to assess the effectiveness, tolerability, and safety of ferric carboxymaltose in the management of iron deficiency anemia in pregnant women. <i>Anemia</i>. 2019;2019:4640635. doi:10.1155/2019/4640635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/31781389/pubmed" id="31781389" target="_blank">31781389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27856776">
<a name="27856776"></a>Winkelman JW, Armstrong MJ, Allen RP, et al. Practice guideline summary: treatment of restless legs syndrome in adults: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. <i>Neurology.</i> 2016;87(24):2585-2593. doi:10.1212/WNL.0000000000003388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/27856776/pubmed" id="27856776" target="_blank">27856776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27583315">
<a name="27583315"></a>World Health Organization (WHO). Guideline: iron supplementation in postpartum women. World Health Organization; 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-carboxymaltose-drug-information/abstract-text/27583315/pubmed" id="27583315" target="_blank">27583315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. https://iris.who.int/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf?sequence=22. Published 2011. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Serum ferritin concentrations for the assessment of iron status in individuals and populations: technical brief. https://iris.who.int/bitstream/handle/10665/337666/9789240008526-eng.pdf?sequence=1. Published 2020. Accessed December 11, 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 90237 Version 173.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
